Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

Current Oncology

Volumn 16, Issue 1, 2009, Pages 14-24

  Melosky, Barbara ^a   Burkes, R ^b   Rayson, D ^c   Alcindor, T ^d   Shear, N ^e   Lacouture, M ^f  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti EGFR; Canadian recommendations; Colorectal cancer; Dermatologic toxicity; EGFRI; Epidermal growth factor receptor inhibitor; Gastrointestinal malignancy; Proactive management; Side effects; Skin rash; Treatment algorithm

Indexed keywords

CETUXIMAB; CLINDAMYCIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; K RAS PROTEIN; MINOCYCLINE; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PLACEBO; STEROID; SUNSCREEN; TAZAROTENE; TETRACYCLINE; TRIAMCINOLONE ACETONIDE;

ANTINEOPLASTIC ACTIVITY; BLISTER; CANADA; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONSENSUS DEVELOPMENT; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EVIDENCE BASED MEDICINE; HAIR DISEASE; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; MUCOSA INFLAMMATION; NAIL DISEASE; OVERALL SURVIVAL; PAIN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACOGENETICS; PROTEIN EXPRESSION; PRURITUS; PUSTULE; PYOGENIC GRANULOMA; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SKIN BURNING SENSATION; SKIN FISSURE; SKIN IRRITATION; SKIN TOXICITY; SLEEP DISORDER; SURVIVAL TIME; TELANGIECTASIA;

EID: 65749101493     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i1.361     Document Type: Review

References (44)

1. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12.
2. Rowinsky EK. The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-57.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
4. ImClone Systems. Erbitux (cetuximab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2007.
5. Amgen Canada. Vectibix (panitumumab) [product monograph]. Mississauga, ON: Amgen; 2008.
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
7. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
8. Karapetis C, Khambata-Ford S, Jonker D, et al. KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer. Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care [abstract]. In: Scientific Highlights [press kit release]. European Society for Medical Oncology (ESMO) International Symposium. 10th World Congress on Gastrointestinal Cancer; June 25-28, 2008; Barcelona, Spain. [Available online at: Www.worldgicancer.com/WCGI/ WGIC08/WGIC08_pressinfo_combined.pdf; cited December 15, 2008]
9. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol 2007;25;1658-64.
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
11. Pérez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8(suppl 1):S7-14.
12. Pérez-Soler R, Van Cutsem E. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology 2007;21(suppl 5):10-16.
13. Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs 2006;22(suppl 1):28-34.
14. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology 2007;72:152-9.
15. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 2007;21(suppl 5): 34-6.
16. Busam KJ, Tan LK, Granter SR, et al. Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol 1999;12:786-93.
17. Mitchell EP, Pérez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology 2007;21(suppl 5):4-9.
18. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005;4:650-8.
19. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.
20. Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9:59-60.
21. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
22. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Toxicity Criteria Manual: Common Toxicity Criteria, Version 2.0. Bethesda, MD: CTEP; 1999. [Available online at: Ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ ctcmanual_v4_10-4-99.pdf; cited June 8, 2008]
23. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238-41.
24. Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: U.S. perspective. Oncology 2007;21(suppl 5):17-21.
25. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: A dermatology-oncology perspective. Skin Therapy Lett 2007;12:1-5.
26. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 2008;12:283-90.
27. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006;155:852-4.
28. Cohen R, Falcey J, Paulter V, Fetzer K, Waksal H. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors [abstract 1862]. Proc Am Soc Clin Oncol 2000;19:474a. [Available online at: Www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=2&abstractID= 500027; cited December 15, 2008]
29. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/ EGFR inhibitor -associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56.
30. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: CTEP; 2006. [Available online at: Ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ctcaev3.pdf; cited June 27, 2008]
31. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007;12:610-21.
32. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606.
33. Lacouture ME, Basti S, Patel J, Benson A 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-8.
34. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-6.
35. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-53.
36. Mitchell EP, LaCouture M, Shearer H, et al. Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (mCRC) patients receiving panitumumab+FOLFIRI or irinotecan-only chemotherapy as second-line treatment [abstract O-021]. In: Scientific Highlights [press kit release]. European Society for Medical Oncology (ESMO) International Symposium. 10th World Congress on Gastrointestinal Cancer; June 25-28, 2008; Barcelona, Spain. [Available online at: Www.worldgicancer.com/WCGI/WGIC08/ WGIC08_pressinfo_combined.pdf; cited December 15, 2008]
37. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
38. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8.
39. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, singlearm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-8.
40. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK, pharmacodynamic (PD) and efficacy data [abstract 4037]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=47&abstractID=34662; cited December 15, 2008]
41. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32:71-4.
42. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23;165-74.
43. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75:453-63.
44. Nieman GF, Zerler BR. A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 2001;8:317-25.